Emerging studies suggest Retatru tide , a dual activator targeting both GLP-1 and glucose-dependent insulinotropic polypeptide , may represent a promising development for weight management . Early patient investigations have demonstrated substantial decreases in visceral fat , conceivably surpassing existing weight-loss medications . However , more